FDA declines to approve nasal spray alternative to EpiPen, company says

  • 📰 abc7newsbayarea
  • ⏱ Reading Time:
  • 39 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 51%

United States News News

United States United States Latest News,United States United States Headlines

ARS Pharma shares traded down sharply in pre-market trading.

This is a breaking news story please check back for updates.Regulators at the U.S. Food and Drug Administration declined to approve a needle-free nasal spray equivalent to an EpiPen, pending further study, according to the company developing it.

ARS Pharma developed the product, Neffy, which is inhaled and would have been available by prescription if approved. Neffy would be a first-of-its-kind alternative to an EpiPen, which is commonly used to treat anaphylaxis, or severe allegoric reactions. The FDA said they haven't yet seen enough evidence to support approval. The company will have an opportunity to run additional studies and apply for approval again.

'We are very surprised by this action and the late requirement at this time to change the repeat-dose study from a post-marketing requirement, which we had previously aligned on with FDA, to a pre-approval requirement, particularly given the positive Advisory Committee vote," Richard Lowenthal, CEO of ARS, said in

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 529. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA declines to approve nasal spray alternative to EpiPen, seeking further study, company saysARS Pharma shares traded down sharply in pre-market trading.
Source: ABC - 🏆 471. / 51 Read more »

FDA declines to approve nasal spray alternative to EpiPen, company saysARS Pharma shares traded down sharply in pre-market trading.
Source: ABC7NY - 🏆 592. / 51 Read more »